The board of directors of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that the Company has received a clinical trial notice approving the investigational new drug application for the innovative drug SKB518 for injection developed by the Company from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on June 17, 2024. SKB518 for injection is a novel ADC drug with proprietary intellectual property rights developed by the Company based on the biological characteristics of the target and using the technology of the "OptiDCTM" platform, which has demonstrated promising efficacy and safety window in preclinical studies and is intended to be used for the treatment of advanced solid tumors. In accordance with the clinical trial notice issued by the NMPA, the Company plans to organize and implement a clinical trial of SKB518 for injection.